Neurocrine Biosciences, Inc. (NBIX)
142.70
-0.59
(-0.41%)
USD |
NASDAQ |
Oct 23, 16:00
142.71
+0.01
(+0.01%)
After-Hours: 20:00
Neurocrine Biosciences Enterprise Value : 14.51B for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 14.51B |
| October 22, 2026 | 14.57B |
| October 21, 2026 | 14.37B |
| October 20, 2026 | 14.44B |
| October 19, 2026 | 13.93B |
| October 16, 2026 | 13.80B |
| October 15, 2026 | 13.93B |
| October 14, 2026 | 13.82B |
| October 13, 2026 | 13.74B |
| October 12, 2026 | 14.38B |
| October 09, 2026 | 14.48B |
| October 08, 2026 | 14.36B |
| October 07, 2026 | 14.59B |
| October 06, 2026 | 14.80B |
| October 05, 2026 | 14.66B |
| October 02, 2026 | 14.56B |
| October 01, 2026 | 14.31B |
| September 30, 2026 | 14.42B |
| September 29, 2026 | 14.07B |
| September 28, 2026 | 14.28B |
| September 25, 2026 | 14.07B |
| September 24, 2026 | 14.13B |
| September 23, 2026 | 14.18B |
| September 22, 2026 | 14.46B |
| September 21, 2026 | 14.64B |
| Date | Value |
|---|---|
| September 18, 2026 | 14.87B |
| September 17, 2026 | 15.44B |
| September 16, 2026 | 15.20B |
| September 15, 2026 | 15.25B |
| September 14, 2026 | 15.99B |
| September 11, 2026 | 15.88B |
| September 10, 2026 | 15.92B |
| September 09, 2026 | 15.77B |
| September 08, 2026 | 15.77B |
| September 04, 2026 | 15.83B |
| September 03, 2026 | 16.10B |
| September 02, 2026 | 16.04B |
| September 01, 2026 | 15.94B |
| August 31, 2026 | 15.66B |
| August 28, 2026 | 15.66B |
| August 27, 2026 | 15.85B |
| August 26, 2026 | 15.92B |
| August 25, 2026 | 15.59B |
| August 24, 2026 | 15.56B |
| August 21, 2026 | 15.51B |
| August 20, 2026 | 15.55B |
| August 19, 2026 | 15.81B |
| August 18, 2026 | 15.68B |
| August 17, 2026 | 15.71B |
| August 14, 2026 | 15.53B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Amgen, Inc. | 280.78B |
| BioCryst Pharmaceuticals, Inc. | 2.436B |
| Halozyme Therapeutics, Inc. | 16.24B |
| Iovance Biotherapeutics, Inc. | 6.131B |
| Precigen, Inc. | 2.276B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 144.40M |
| Revenue (Quarterly) | 959.00M |
| Total Expenses (Quarterly) | 814.60M |
| EPS Diluted (Quarterly) | 1.386 |
| Gross Profit Margin (Quarterly) | 95.87% |
| Profit Margin (Quarterly) | 15.06% |
| Earnings Yield | 4.78% |
| Operating Earnings Yield | 5.46% |
| Normalized Earnings Yield | 4.688 |